Alpha MOS : Development acceleration booster for BOYDSense’s breath analyser platform for people living with Diabetes thanks to the support of the European Innovation Council (EIC)

PRESS RELEASE

Toulouse, 30 August 2022, at 6:10 p.m.

Development acceleration booster for BOYDSense's breath analyser platform

for people living with Diabetes thanks to the support of the European

Innovation Council (EIC)

BOYDSense SAS, subsidiary of Alpha MOS (Euronext Paris, ISIN: FR0013421286 ALNEO), was chosen in December 2021 by the EIC under its Horizon Europe funding program (2021-2027), co-managedwith the European Commission (EC).

The receipt of the first part of this €2.5M non-dilutive financing now allows BOYDSense to take several key steps in the development and industrialization of its non-invasivedevice. Firstly, the recruitment of engineers and scientists for the R&D department in Toulouse, and secondly, the acceleration of clinical trials in Europe to rapidly validate the device. The EIC's help also enables the company to obtain the ISO 13485 certificate, a necessary step to comply with international medical device regulations.

Finally, more prototypes will be produced, so that clinical trials can be conducted in parallel and clinical evidence obtained faster.

"This grant will help us to get more clinical trial data and thus improve our algorithm. It's a big step for BOYDSense and patients living with Diabetes" as the painful blood glucose monitoring can soon be replaced by non-invasivesaid Ben Delhey, CEO of BOYDSense.

About BOYDSense

BOYDSense, SAS. is a medical technology company developing affordable, non-invasive health monitoring platform for measuring different biomarkers via exhaled breath. Breath-based metabolomics focuses on the capture, identification, and quantification of volatile organic compound (VOC) biomarker patterns in human breath and using them to diagnose and monitor chronic diseases, such as diabetes. The BOYDSense platform will also allow consumers and healthcare providers to use breath as a non-invasive medium to detect and monitor diseases like cancer, obesity, asthma, and others. BOYDSense's first product under development, named Lassie™, is an affordable device that allows people with diabetes to accurately measure blood glucose values without the cost and pain.

BOYDSense is an Alpha MOS company, the leader in volatile organic compound analysis.

For more information, please visit: www.boydsense.com.

This press release, and the information contained herein, does not constitute a solicitation of an order

to purchase or subscribe for securities in France or in countries other than France.

1

PRESS RELEASE

About Alpha MOS

Alpha MOS (Euronext Paris, ISIN: FR0013421286 ALM, Code mnemonic: ALNEO) specializes in sensory analysis solutions and is the world leader in the manufacture of electronic noses, tongues, and eyes for industrial use. Founded in 1993, Alpha MOS is an international company with offices in France, China, and the USA. It manages a fleet of more than 1000 instruments installed throughout the world, mainly in the food, beverage, and packaging industries. Alpha MOS continually invests in research and development to meet market needs and innovates to develop the consumer sensory analysis market.

For more information, please visit : www.alpha-mos.com

Company contacts

BOYDSense: Ben Delhey - CEO - [phone]

[e-mail]

Alpha MOS: Pierre Sbabo - CEO - [phone]

[e-mail]

Press contact

Lucas Rennesson - Mascaret - [e-mail]- [phone]

This press release, and the information contained herein, does not constitute a solicitation of an order

to purchase or subscribe for securities in France or in countries other than France.

2